Ai-driven platform for terpene-based neuropathy treatment discovery
An AI-driven platform using robotics and zebrafish models to discover effective terpene combinations for neuropathy treatment. This system accelerates the development of novel, safe, and consumer-friendly OTC neuropathic pain treatments.
Overview
This innovative platform leverages AI, robotics, and zebrafish models to expedite the discovery of effective terpene-based treatments for neuropathy. By automating the process of mixing and testing terpenes, this system identifies promising combinations for neuropathic pain relief. The use of AI allows for rapid analysis and prediction of the most effective terpene mixtures, which can lead to the development of novel, safe, and consumer-friendly over-the-counter (OTC) neuropathic pain treatments.
Technical specifications
- AI-driven compound selection: Utilizes cheminformatic modelling and bioactivity data to predict terpene candidates with analgesic or neuroprotective potential.
- Liquid handling robots: Execute precise and reproducible dosing for both individual and combinatorial administration of terpenes.
- Zebrafish models: Used as live models to observe pain-related behaviours and gene expression changes.
- Optimization: Bayesian algorithms refine terpene combinations for maximum therapeutic effect and minimal toxicity.
- Versatility: Platform can be adapted for other applications, including optimizing microneedle and topical formulations.
Technology readiness level
This platform is currently at Technology Readiness Level 4. It has been validated in a laboratory setting and is undergoing further development to transition optimized terpene formulations into consumer-friendly delivery formats, with a timeline for further validation set at five months.
About Queen Mary University of London
Queen Mary University of London is a comprehensive public research university within the University of London, serving a large and diverse community across campuses in East and Central London. Integration with a major NHS hospital network provides co‑located clinical and translational facilities and access to trial infrastructure and real‑world datasets. An on‑site innovation ecosystem with wet‑lab and startup space, plus proximity to the City and Tech City, connects researchers to London’s finance and digital industry clusters. Research is supported by competitive funding from UK Research and Innovation councils, the National Institute for Health and Care Research, and leading UK charities. A dedicated technology transfer company manages IP, licensing, consultancy, spinouts, and Knowledge Transfer Partnerships to streamline collaboration.
delivered to your inbox.